3562. Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers.
作者: Jan Vincent B Beltran.;Fang-Ping Lin.;Chaw-Liang Chang.;Tai-Ming Ko.
来源: Circulation. 2023年148卷22期1778-1796页
Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) share similar clinical manifestations, including cardiovascular complications, suggesting similar underlying immunopathogenic processes. Aberrant neutrophil activation may play a crucial role in the shared pathologies of KD and MIS-C; however, the associated pathogenic mechanisms and molecular drivers remain unknown.
3563. Hypertrophic Cardiomyopathy Secondary to RAF1 Cysteine-Rich Domain Variants.
作者: Dominic E Fullenkamp.;Ryan M Jorgensen.;Desiree F Leach.;Arjun Sinha.;Isabella M Salamone.;Jamie R Johnston.;Lisa M Dellefave-Castillo.;Lubna Choudhury.;Elizabeth M McNally.;Lisa D Wilsbacher.
来源: Circ Genom Precis Med. 2023年16卷6期e004262页 3565. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
作者: Aish Sinha.;Haseeb Rahman.;Abdel Douiri.;Ozan M Demir.;Kalpa De Silva.;Brian Clapp.;Ian Webb.;Ankur Gulati.;Pedro Pinho.;Utkarsh Dutta.;Howard Ellis.;Ajay M Shah.;Amedeo Chiribiri.;Michael Marber.;Andrew J Webb.;Divaka Perera.
来源: Circulation. 2024年149卷1期36-47页
Angina with nonobstructive coronary arteries is a common condition for which no effective treatment has been established. We hypothesized that the measurement of coronary flow reserve (CFR) allows identification of patients with angina with nonobstructive coronary arteries who would benefit from anti-ischemic therapy.
3567. Letter by Teng et al Regarding the Article, "Endothelial HDAC1-ZEB2-NuRD Complex Drives Aortic Aneurysm and Dissection Through Regulation of Protein S-Sulfhydration".3568. Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
作者: Sauyeh K Zamani.;Satyam Sarma.;James P MacNamara.;Linda S Hynan.;Mark J Haykowsky.;Christopher M Hearon.;Denis Wakeham.;Tiffany Brazile.;Benjamin D Levine.;Vlad G Zaha.;Michael D Nelson.
来源: Circulation. 2023年148卷18期1410-1412页 3571. Next Generation, Modifiable Cardiometabolic Biomarkers: Mitochondrial Adaptation and Metabolic Resilience: A Scientific Statement From the American Heart Association.
作者: Michele Mietus-Snyder.;Amanda M Perak.;Susan Cheng.;Laura L Hayman.;Norrisa Haynes.;Peter J Meikle.;Svati H Shah.;Shakira F Suglia.; .
来源: Circulation. 2023年148卷22期1827-1845页
Cardiometabolic risk is increasing in prevalence across the life span with disproportionate ramifications for youth at socioeconomic disadvantage. Established risk factors and associated disease progression are harder to reverse as they become entrenched over time; if current trends are unchecked, the consequences for individual and societal wellness will become untenable. Interrelated root causes of ectopic adiposity and insulin resistance are understood but identified late in the trajectory of systemic metabolic dysregulation when traditional cardiometabolic risk factors cross current diagnostic thresholds of disease. Thus, children at cardiometabolic risk are often exposed to suboptimal metabolism over years before they present with clinical symptoms, at which point life-long reliance on pharmacotherapy may only mitigate but not reverse the risk. Leading-edge indicators are needed to detect the earliest departure from healthy metabolism, so that targeted, primordial, and primary prevention of cardiometabolic risk is possible. Better understanding of biomarkers that reflect the earliest transitions to dysmetabolism, beginning in utero, ideally biomarkers that are also mechanistic/causal and modifiable, is critically needed. This scientific statement explores emerging biomarkers of cardiometabolic risk across rapidly evolving and interrelated "omic" fields of research (the epigenome, microbiome, metabolome, lipidome, and inflammasome). Connections in each domain to mitochondrial function are identified that may mediate the favorable responses of each of the omic biomarkers featured to a heart-healthy lifestyle, notably to nutritional interventions. Fuller implementation of evidence-based nutrition must address environmental and socioeconomic disparities that can either facilitate or impede response to therapy.
3572. Projected Change in the Burden of Excess Cardiovascular Deaths Associated With Extreme Heat by Midcentury (2036-2065) in the Contiguous United States.
作者: Sameed Ahmed M Khatana.;Lauren A Eberly.;Ashwin S Nathan.;Peter W Groeneveld.
来源: Circulation. 2023年148卷20期1559-1569页
Climate change is causing an increase in extreme heat. Individuals with cardiovascular disease are at high risk of heat-related adverse health effects. How the burden of extreme heat-associated cardiovascular deaths in the United States will change with the projected rise in extreme heat is unknown.
3573. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
作者: Auke T Bergeman.;Krystien V V Lieve.;Dania Kallas.;J Martijn Bos.;Ferran Rosés I Noguer.;Isabelle Denjoy.;Esther Zorio.;Janneke A E Kammeraad.;Puck J Peltenburg.;Katie Tobert.;Takeshi Aiba.;Joseph Atallah.;Fabrizio Drago.;Anjan S Batra.;Ramon Brugada.;Martin Borggrefe.;Sally-Ann B Clur.;Moniek G P J Cox.;Andrew Davis.;Santokh Dhillon.;Susan P Etheridge.;Peter Fischbach.;Sonia Franciosi.;Kristina Haugaa.;Minoru Horie.;Christopher Johnsrude.;Austin M Kane.;Ulrich Krause.;Sit-Yee Kwok.;Martin J LaPage.;Seiko Ohno.;Vincent Probst.;Jason D Roberts.;Tomas Robyns.;Frederic Sacher.;Christopher Semsarian.;Jonathan R Skinner.;Heikki Swan.;Terezia Tavacova.;Svjetlana Tisma-Dupanovic.;Jacob Tfelt-Hansen.;Sing-Chien Yap.;Prince J Kannankeril.;Antoine Leenhardt.;Janice Till.;Shubhayan Sanatani.;Michael W T Tanck.;Michael J Ackerman.;Arthur A M Wilde.;Christian van der Werf.
来源: Circulation. 2023年148卷25期2029-2037页
In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia.
3574. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
作者: Toru Kondo.;Jawad H Butt.;James P Curtain.;Pardeep S Jhund.;Kieran F Docherty.;Brian L Claggett.;Muthiah Vaduganathan.;Erasmus Bachus.;Adrian F Hernandez.;Carolyn S P Lam.;Silvio E Inzucchi.;Felipe A Martinez.;Rudolf A de Boer.;Mikhail N Kosiborod.;Akshay S Desai.;Lars Køber.;Piotr Ponikowski.;Marc S Sabatine.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2023年16卷12期e010898页
Although elevated resting heart rate (HR) is associated with a higher risk of cardiovascular events in patients with heart failure with reduced ejection fraction in sinus rhythm (SR), the relationship between HR and outcomes among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction and in those with atrial fibrillation (AF) is uncertain. The aims of this study were to examine the association between baseline HR and outcomes across the range of left ventricular ejection fraction, in patients with and without AF, and evaluate the effect of dapagliflozin according to HR.
3575. MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
作者: Puneeth Shridhar.;Michael S Glennon.;Soumojit Pal.;Christina J Waldron.;Ethan J Chetkof.;Payel Basak.;Nicolas G Clavere.;Dipanjan Banerjee.;Sebastien Gingras.;Jason R Becker.
来源: Circulation. 2023年148卷23期1870-1886页
Microvasculature dysfunction is a common finding in pathologic remodeling of the heart and is thought to play an important role in the pathogenesis of hypertrophic cardiomyopathy (HCM), a disease caused by sarcomere gene mutations. We hypothesized that microvascular dysfunction in HCM was secondary to abnormal microvascular growth and could occur independent of ventricular hypertrophy.
3576. Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair.
作者: Jie Feng.;Yandong Li.;Yan Li.;Qianqian Yin.;Haotong Li.;Jun Li.;Bin Zhou.;Jian Meng.;Hong Lian.;Mengge Wu.;Yahuan Li.;Kefei Dou.;Weihua Song.;Bin Lu.;Lihui Liu.;Shengshou Hu.;Yu Nie.
来源: Circulation. 2024年149卷13期1004-1015页
The adult mammalian heart is incapable of regeneration, whereas a transient regenerative capacity is maintained in the neonatal heart, primarily through the proliferation of preexisting cardiomyocytes. Neonatal heart regeneration after myocardial injury is accompanied by an expansion of cardiac fibroblasts and compositional changes in the extracellular matrix. Whether and how these changes influence cardiomyocyte proliferation and heart regeneration remains to be investigated.
3577. Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction.
作者: Janet I Ma.;Emily K Zern.;Juhi K Parekh.;Ndidi Owunna.;Nona Jiang.;Dongyu Wang.;Paula K Rambarat.;Eugene Pomerantsev.;Michael H Picard.;Jennifer E Ho.
来源: Circ Heart Fail. 2023年16卷11期e010524页
Right ventricular (RV) dysfunction is associated with increased mortality across a spectrum of cardiovascular diseases. The role of obesity in RV dysfunction and adverse outcomes is unclear.
3578. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
作者: Michel Azizi.;Andrew S P Sharp.;Naomi D L Fisher.;Michael A Weber.;Melvin D Lobo.;Joost Daemen.;Philipp Lurz.;Felix Mahfoud.;Roland E Schmieder.;Jan Basile.;Michael J Bloch.;Manish Saxena.;Yale Wang.;Kintur Sanghvi.;J Stephen Jenkins.;Chandan Devireddy.;Florian Rader.;Philippe Gosse.;Lisa Claude.;Dimitri A Augustin.;Candace K McClure.;Ajay J Kirtane.; .
来源: Circulation. 2024年149卷10期747-759页
The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN versus sham at 6 months, after the blinded addition of antihypertensive treatments (AHTs), we pooled individual patient data across these 3 similarly designed trials.
3579. Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial.
作者: Josep Rodés-Cabau.;Henrique Barbosa Ribeiro.;Siamak Mohammadi.;Vicenç Serra.;Talal Al-Atassi.;Andres Iñiguez.;Victoria Vilalta.;Luis Nombela-Franco.;José Ignacio Sáez de Ibarra Sánchez.;Vincent Auffret.;Jessica Forcillo.;Lenard Conradi.;Marina Urena.;Cesar Moris.;Antonio Muñoz-Garcia.;Jean-Michel Paradis.;Eric Dumont.;Dimitri Kalavrouziotis.;Pablo Maria Pomerantzeff.;Vitor Emer Egypto Rosa.;Mariana Pezzute Lopes.;Carles Sureda.;Victor Alfonso Jimenez Diaz.;Carlos Giuliani.;Marisa Avvedimento.;Emilie Pelletier-Beaumont.;Philippe Pibarot.; .
来源: Circulation. 2024年149卷9期644-655页
The optimal treatment in patients with severe aortic stenosis and small aortic annulus (SAA) remains to be determined. This study aimed to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA.
|